Multidrug-Resistant Nontuberculous Mycobacteria Isolated from Cystic Fibrosis Patients by Campanini Candido, Pedro Henrique et al.
Multidrug-Resistant Nontuberculous Mycobacteria Isolated from
Cystic Fibrosis Patients
Pedro Henrique Campanini Cândido,a Luciana de Souza Nunes,b Elizabeth Andrade Marques,c Tânia Wrobel Folescu,d
Fábrice Santana Coelho,e Vinicius Calado Nogueira de Moura,f Marlei Gomes da Silva,f Karen Machado Gomes,f
Maria Cristina da Silva Lourenço,g Fábio Silva Aguiar,a Fernanda Chitolina,h Derek T. Armstrong,i Sylvia Cardoso Leão,j
Felipe Piedade Gonçalves Neves,k Fernanda Carvalho de Queiroz Mello,h Rafael Silva Duartef
Programa de Pós Graduação em Clínica Médica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazila; Programa de
Pós Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazilb; Departamento de Microbiologia, Imunologia e Parasitologia,
Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazilc; Instituto Fernandes Figueira, Rio de Janeiro, Brazild; Hospital Universitário
Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Brazile; Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazilf; Instituto de
Pesquisa Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazilg; Instituto de Doenças do Tórax, Rio de Janeiro, Brazilh; Johns Hopkins University, Baltimore, MD,
USAi, Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazilj; Instituto Biomédico,
Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazilk
Worldwide, nontuberculous mycobacteria (NTM) have become emergent pathogens of pulmonary infections in cystic fibrosis
(CF) patients, with an estimated prevalence ranging from 5 to 20%. This work investigated the presence of NTM in sputum sam-
ples of 129 CF patients (2 to 18 years old) submitted to longitudinal clinical supervision at a regional reference center in Rio de
Janeiro, Brazil. From June 2009 toMarch 2012, 36 NTM isolates recovered from 10 (7.75%) out of 129 children were obtained.
Molecular identification of NTMwas performed by using PCR restriction analysis targeting the hsp65 gene (PRA-hsp65) and
sequencing of the rpoB gene, and susceptibility tests were performed that followed Clinical and Laboratory Standards Institute
recommendations. For evaluating the genotypic diversity, pulsed-field gel electrophoresis (PFGE) and/or enterobacterial repeti-
tive intergenic consensus sequence PCR (ERIC-PCR) was performed. The species identified wereMycobacterium abscessus
subsp. bolletii (n 24),M. abscessus subsp. abscessus (n 6),Mycobacterium fortuitum (n 3),Mycobacterium marseillense
(n 2), andMycobacterium timonense (n 1). Most of the isolates presented resistance to five or more of the antimicrobials
tested. Typing profiles were mainly patient specific. The PFGE profiles indicated the presence of two clonal groups forM. absces-
sus subsp. abscessus and five clonal groups forM. abscesssus subsp. bolletii, with just one clone detected in two patients. Given
the observed multidrug resistance patterns and the possibility of transmission between patients, we suggest the implementation
of continuous and routine investigation of NTM infection or colonization in CF patients, including countries with a high burden
of tuberculosis disease.
The survival rate for cystic fibrosis (CF) patients has increased inrecent years, mainly due to early diagnosis, nutritional thera-
pies, and the discovery of new antimicrobial agents. Acute or
chronic pulmonary infections caused by bacteria are the major
causes of morbidity and mortality in CF patients (1). For the last
20 to 25 years, nontuberculous mycobacteria (NTM) have
emerged as newly detected pathogens in CF patients. Several cen-
ters around the world have reported the isolation of NTM in the
respiratory tracts of CF patients. Nowadays, this prevalence varies
between 5 and 20% (2, 3, 4, 5, 6, 7), with most of those cases
(90%) caused by species of the Mycobacterium avium complex
(MAC) and the Mycobacterium abscessus group (5, 8, 9).
NTM have been found and described in diverse environments
and clinical scenarios, due to their adaptive biological properties
and opportunistic potentials. It is considered that selective pres-
sure in hospital environments, predominantly caused by excessive
antibiotic use, has contributed to NTM resistance to a large num-
ber of antibiotics and disinfection processes, such as antitubercu-
losis agents (i.e., isoniazid and pyrazinamide), glutaraldehyde,
and organomercury compounds (10). However, NTM usually
present as susceptible to aminoglycosides and macrolides (11, 12,
13). Cefoxitin, quinolone, and tetracyclines are other options for
drug treatment, specifically for rapidly growing mycobacteria
(RGM) infections. However, similar to other bacteria commonly
associated with CF infections, NTM resistant strains have been
reported. Broda et al. (14) reported clarithromycin susceptibility
rates of 57% inMycobacterium abscessus isolates. Binder et al. (13)
suggested that all CF patients undertake evaluation for NTM dis-
ease, due to continual exposure to macrolides for other bacterial
infections.
In Brazil, microbiological studies involving CF patients are
rare, withmost focused on infections caused byBurkholderia ceno-
cepacia and/or Pseudomonas aeruginosa (2). The Instituto Fer-
nandes Figueira (IFF) is a large unit that belongs to the Oswaldo
Cruz Foundation (FIOCRUZ) and is the major clinical research
center for CF children in Rio de Janeiro state and in the country of
Brazil. Microbiological surveillance of these patients is common;
however, investigation of NTM disease has only been performed
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since June 2009. Given the lack of epidemiological information on
NTM in Brazilian CF children and the emergence of NTM as
pathogens in this population worldwide, the significance of devel-
oping research on NTM and the association with CF is definitely
warranted. Epidemiological studies in European cohorts have
demonstrated a high prevalence ofNTM infections inCF patients,
but these countries have lower disease burdens of tuberculosis
(TB). Brazil is one of the main high-TB-burden countries, and
large epidemics of NTM infections have been described in recent
literature (10). Therefore, it is necessary to undergo studies look-
ing at the prevalence of NTM in CF patients to better understand
the magnitude of this emergence in different countries globally.
This is the first complete study providing genotypic identifica-
tion, antimicrobial susceptibility profiles, and strain diversity of
nontuberculousmycobacteria isolates recovered fromCFpatients
in Brazil.
MATERIALS AND METHODS
Mycobacterial isolates. From June 2009 to March 2012, spontaneous
sputum samples from CF patients monitored at a local reference center
(IFF-FIOCRUZ, Rio de Janeiro, Brazil) were sent monthly to the Bacteri-
ology andMycobacteriology laboratories at Hospital Universitário Pedro
Ernesto, Rio de Janeiro, Brazil, for routine microbiological investigation.
Sputum samples were processed with NALC-NaOH and 5% oxalic acid
decontamination as recommended by the National Guideline for TB and
NTM Laboratory Surveillance (15). A total of 36 NTM isolates were re-
covered from sputum samples obtained from 10 of 129 children (7.75%; 2
to 18 years old).
Species identification. A loopful of bacterial growth from Löwen-
stein-Jensen medium was mixed in 100 l of TE (Tris-HCl at 10 mM,
EDTA at 1mM; pH 8.0). The suspensions were boiled at 100°C for 10min
and immediately incubated at 20°C for 12 h. Genotypic identification of
the 36 isolates was performed by using PCR restriction analysis targeting
the hsp65 gene (PRA-hsp65) with the primers TB11, 5=-ACCAACGATG
GTGTGTCCAT-3=, and TB12, 5=-CTTGTCGAACCGCATACCCT-3=
(16). A denaturation step of 95°C for 5 min was followed by 45 cycles of
94°C for 1min, 60°C for 1min, and 72°C for 1min and by a final extension
of 72°C for 7 min. Amplicons were submitted to individual digestions
with the restriction enzymes BstEII and HaeIII (Promega Corporation,
Madison, WI) for 3 h at 60°C and 37°C, respectively. The digestion prod-
ucts were analyzed after 4% agarose gel electrophoresis at 3 V/cm using
25- and 50-bp DNA ladders (Invitrogen). The PRA-hsp65 profiles were
analyzed using the algorithm available at the PRA site (http://app.chuv.ch
/prasite/index.html).
All the results were confirmed by partial sequencing of the rpoB gene
by using the primersMyco F (5=-GCAAGGTCACCCCGAAGGG-3=) and
Myco R (5=-AGCGGCTGCTGGGTGATCATC-3=), according to the
methodology described by Adekambi, Colson, and Drancourt (17). Re-
gion V rpoB gene sequences were submitted for BLAST similarity analysis
(Basic Local Alignment Tool; http://www.ncbi.nlm.nih.gov/BLAST)
and comparison to the sequences from M. abscessusT ATCC 19977
(JF346872), “M. massilienseT” CIP 108297 (EU254721.1), “M. bolletiiT”
CCUG 50184 (DQ987717.1), the M. abscessus subsp. bolletii epidemic
strain INCQS 594 (EU117207.1),M. fortuitum ATCC 6841 (JF346874.1),
M. marseillense strain 62863 (EF584444.1), and M. timonense strain
3256799 (EF584435.1).
Antimicrobial susceptibility testing. The RGM isolates were tested
against dilutions of amikacin (128 to 1g/ml), cefoxitin (256 to 2g/ml),
ciprofloxacin (16 to 0.125 g/ml), clarithromycin (64 to 0.5 g/ml),
doxycycline (32 to 0.25 g/ml), moxifloxacin (16 to 0.125 g/ml), and
sulfamethoxazole-trimethoprim (16/304 to 0.5/9.5 g/ml). Slowly grow-
ing mycobacteria (SGM) were tested against amikacin (128 to 1 g/ml),
clarithromycin (64 to 0.5 g/ml), streptomycin (16 to 0.125 g/ml),
ethambutol (16 to 0.125 g/ml), moxifloxacin (16 to 0.125 g/ml), and
rifampin (16 to 0.125 g/ml). MICS were measured using the microdilu-
tion broth method proposed by the Clinical Laboratory and Standards
Institute (CLSI) (18). Only noninducible clarithromycin patterns (read-
ing at 3 to 5 days) were evaluated in this study for M. abscessus.
The breakpoints proposed by Siddiqii and collaborators (19) were
used to determine the resistance profiles of amikacin, streptomycin,
ethambutol, and rifampin for SGM.
ERIC-PCR. Enterobacterial repetitive intergenic consensus PCR
(ERIC-PCR) was performed for the pulsed-field gel electrophoresis
(PFGE)-nontypeable isolates in order to verify the genotypic diversity
among them. The primers ERIC1R (5=-ATGTAAGCTCCTGGGGATTC
AC-3=) and ERIC2 (5=-AAGTAAGTGACTGGGGTGAGCG-3=) were ap-
plied (20). Themixturewas heated at 95°C for 4min, followed by 35 cycles
of 95°C for 45 s, 52°C for 1min, and 70°C for 10min and a last step of 70°C
for 20 min. PCR products were analyzed after 2% gel electrophoresis (5
V/cm) and stained with ethidium bromide and using a 100-bp DNA lad-
der (Invitrogen). The profiles obtained by electrophoresis were analyzed
and compared using the Bionumerics version 6.6 software platform (Ap-
plied Maths, Belgium). Dice’s coefficient was applied, and a dendrogram
based on percentages of similarity was generated by the using the un-
weighted-pair group with arithmetic mean (UPGMA) method. The ge-
notypic grouping was done by automated and visual analyses of the gels,
using a cutoff value of 85% similarity and a tolerance index of 1.5%.
PFGE. PFGE was performed when multiple RGM isolates of the same
species were obtained, in order to verify the genotypic diversity. The M.
abscessus subsp. bolletii strain CRM 0019, which belongs to the BRA100
clone (10), and CCUG 48898 were used as control strains. The cells were
grown inMueller-Hinton agar (Becton, Dickinson and Company, Brazil)
at 35 to 37°C for 7 days. Then, 3 isolated colonies were transferred to a
flask containing 40 ml of Mueller-Hinton broth (Becton, Dickinson and
Company, Brazil) with 0.1% Tween 80 (Sigma-Aldrich, Brazil) and incu-
bated at 37°C. Flasks were shaken at 300  g for at least 4 days until the
optical density at 650 nm (OD650) reached 0.7. The cells from the liquid
culture were harvested by centrifugation at 18,000 g at 4°C for 25 min
(Eppendorf 5810R centrifuge). The pellet was frozen at20°C for 2 h and
then resuspended in STE-Tween 80 buffer (100 mM NaCl, 10 mM Tris
[pH 8.0], 50 mM EDTA [pH 8.0], and 0.1% Tween 80) and mixed vol-
ume/volumewith 2% low-melting-point agarose (Sigma-Aldrich, Brazil).
The plugs were incubated at 4°C for 20 min. Each plug was individually
treated with the solution containing STE plus 10 mg/ml lysozyme and
incubated at 35 to 37°C for 16 h, followed by a new incubation at 4°C for
1 h. The lysis solution was replaced by a solution containing 0.5M EDTA
and 1%Sarkosyl and incubated at 4°C for 1 h. It was then replaced by 0.5M
EDTA, 1% Sarkosyl, and 50 mg/ml proteinase K (Invitrogen Life Tech-
nologies) for each sample. The plugs were incubated at 55°C for 24 h and
at 4°C for 1 h. Each plugwaswashedwith 1TE and incubated for 30min
at 4°C. After this step, a new incubation at 55°C for 1 h with 1 TE and
0.12 mg/ml of phenylmethylsulfonyl fluoride (PMSF) was done. Each
plug was washed three times with 1 TE, with incubation for 30 min at
room temperature. The plugswere stored in 0.5MEDTA (Sigma-Aldrich)
at 4°C. For the restriction enzyme digestion, a 3-mm piece was cut and
washed twice with 1 TE at 4°C for 30min, washed in 0.1%Triton at 4°C
for 2 h, and thendigestedwith 30UDraI (Promega). Plugswere incubated
for 16 h at 37°C and washed with 0.05M at 4°C for 15min. The plugs were
melted at 70°C, and the samples were loaded on a 1% agarose gel (Sigma-
Aldrich) in 5 TE for the PFGE. The Lambda ladder PFG marker (Uni-
science)was used as amolecularweightmarker. The PFGEwas performed
on aCHEFDR III apparatu, using the following settings: initial time of 1.6
s, final time of 21.3 s, running time of 24 h, 6 V/cm, and 120° included
angle. Gels were stained and photographed, and PFGE patterns obtained
were analyzed by using Bionumerics version 6.6 software (AppliedMaths,
Belgium). Dice’s coefficient was applied, and the dendrogram based on
similarity percentages was generated by using the UPGMA method. The
genotypic groupingwas done by automated and visual analyses of the gels,
using a tolerance index of 1.5%.
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Statistical analysis. Evaluation of discriminatory power was per-
formed forM. abscessus subsp. bolletii isolate PFGE patterns by using the
numerical index of discrimination (D), based on Simpson’s index of di-
versity as described by Hunter and Gaston (21).
Ethics. This study was approved by the Brazilian Ethics Committee
andRegional committee (213/08-CEPHUCFFUFRJ, Caracterização Epi-
demiológica e Laboratorial das Micobacterioses do Trato Respiratório
Inferior no Estado doRio de Janeiro). Consent termswere obtained for all
patients included in this study.
RESULTS
M. tuberculosis was not detected among any CF sputum samples.
Considering NTM, 36 isolates were recovered from 10 patients,
and multiple isolations of the same RGM species were observed.
Although we considered the RGM isolated to be associated with
respiratory infections, as recommended by the American Tho-
racic Society (ATS) (22), these organisms were not related to clin-
ical syndromes. A letter identified each patient that had a positive
isolate for NTM. The numbers in parentheses correspond to how
many positive NTM isolates were found in each patient: A (3), B
(3), C (2), D (3), E (2), F (2), G (1), H (15), I (4), J (1).
The analysis of the PRA-hsp65 results showed 22 M. abscessus
type II (BstE II 235/210-HaeIII 200/70/60) restriction profiles, 8
M. abscessus type I (BstE II 235/210-HaeIII 145/70/60), 2 M. chi-
merae/M. intracellulare (BstE II 235/120/100-HaeIII 145/130/60),
and 4 M. fortuitum type II (BstE II 235/120/85-HaeIII 140/120/
60). The partial sequencing of the rpoB gene identified all isolates,
indicating 98 to 100% similarity among 24 M. abscessus subsp.
bolletii isolates and reference strains in the BLAST database, 98%
similarity for 6M. abscessus subsp. abscessus isolates, 99% similar-
ity for 3 M. fortuitum isolates, 100% similarity for 2 M. marseil-
lense isolates, and 100% similarity for 1 M. timonense isolate.
However, these results were different from the PRA-hsp65 results
for 2 isolates (CRM694 andCRM696), frompatientsG andC and
identified asM. chimerae/M. intracellulare. These isolates showed
100% similarity to M. marseillense and, for CRM 747 (from pa-
tient C), 98% similarity to M. abscessus subsp. bolletii. Table 1
shows the results of the comparison between the techniques.
Table 2 shows the MICs against the antimicrobials tested
against RGM. Considering the three MAC isolates, all of them
presented full resistance to streptomycin (MIC, 5 g/ml), and
they also showed intermediate resistance to ethambutol (MIC, 2.5
to 5 g/ml), moxifloxacin (MIC, 2 g/ml), and rifampin (MIC, 1
to 4g/ml). TheM.marseillense isolates (CRM694 andCRM696)
were highly resistant to amikacin (MIC, 8 g/ml), and isolate
CRM 695 showed intermediate levels of resistance to this drug
(MIC, 4 g/ml). All isolates were susceptible to clarithromycin
(MIC, 1 to 2 g/ml).
TheM. abscessus subsp. bolletii isolate CRM 803 from patient J
showed susceptibility to amikacin, ciprofloxacin, and doxycy-
cline. Isolates from patient A initially presented susceptibility to
one of the 7 drugs tested and evolved to complete nonsusceptibil-
ity over a period of 4 months. Isolates from patient B presented
similar characteristics over a period of 15 months. For patient H,
only the first 2 isolates were susceptible to one of the tested drugs,
followed by 13 complete nonsusceptible isolates during the period
of study.
A predominant genotype was found among the isolates of M.
fortuitum, with 2 isolates (CRM 725 and CRM 726) sharing an
identical profile and another isolate (CRM724) with 95% similar-
ity to the others. All isolates were obtained from the same patient,
found nontypeable by PFGE, and analyzed by ERIC-PCR (Fig. 1).
Thirty M. abscessus spp. isolates were analyzed by PFGE, only
and CRM 473, CRM 512, CRM 915, and CRM 949 were classified
as nontypeable due to DNA degradation when we used PFGE or
ERIC-PCR.
Based on PFGE analysis, two distinct genotypes were obtained
among the six isolates ofM. abscessus subsp. abscessus (Fig. 2). The
isolates CRM641 and CRM697 presented an identical profile and
were considered clones. Even though isolate CRM 720 was iso-
lated from the same patient (B), it did not belong to the same
clone, and it was classified within the same genotype, MAA 1. The
isolates CRM 511, CRM 718, and CRM 740, obtained from the
same patient (A), were identical and were classified as genotype
MAA 2.
Among 20 isolates ofM. abscessus subsp. bolletii that were stud-
ied, five different genotypes were obtained (Fig. 3) among seven
related different profiles. The isolates CRM 569, CRM 639, CRM
642, CRM 719, CRM 723, CRM 732, CRM 747, CRM 835, CRM
916, CRM 917, CRM 927, CRM 928, CRM 950, CRM 1009, and
CRM 1010 were classified as genotypeMAB 1.With the exception
of isolate CRM 639, the genotype MAB 1 presented with identical
profiles for all isolates. CRM639 and CRM747 were the only ones
not isolated from the same patient. Genotype MAB 2 presented
twodistinctly related profiles. The isolatesCRM836 andCRM901
were identical and were obtained from the same patient. Isolate
CRM 803 and the reference strain CCUG 48898 presented unique
genotypes, MAB 3 and MAB 4, respectively. We observed that
genotype MAB 5 comprised CRM 640 and CRM 920, following
the patient-specific profile. None of the CF clinical isolates pre-
sented a profile that was similar to the control strains. The D
values for PFGE typing ofMAA andMABwere 1.00 (nonapproxi-
mated 95% confidence interval [CNIA], 0.456 to 1.000) and 0.952
(95% CINA, 0.761 to 1.000), respectively.
DISCUSSION
Several studiesworldwide have reported the prevalence ofNTM in
CF patients. In France, a prevalence of 6.6% for NTM among
1,582 CF patients was reported (6). In Toronto, Canada, the prev-
alence of NTM among 98 CF patients between 6 and 18 years old
was 6.1% (5). In Spain, the prevalence of NTM among 220 CF
patients was 7.72%; however, the patient ages ranged between 6
and 74 years old (3). A study developed in Israel that reported a
prevalence of 22.6% for NTM among 186 CF patients reported
results that differed considerably from those of several other stud-
ies around the world (4). In our country of Brazil, we found only
one study, which showed a prevalence of 11% for NTM among 54
CF adult patients (2). Our study here showed a prevalence of
7.75% for CF patients colonized/infected with NTM.
The PRA-hsp65 had a concordance of 86.11% with the results
obtained from the partial sequencing of rpoB. The isolates CRM
720, CRM 747, and CRM 803 were identified by PRA-hsp65 asM.
abscessus type I, whereas by rpoB sequencing they were identified
asM. abscessus subsp. bolletii. The isolates identified asM. chime-
rae/M. intracellulare by PRA-hsp65 were identified as M. marseil-
lense by rpoB sequencing. The isolate CRM 695 identified as M.
fortuitum by PRA-hsp65 was the one that presented the largest
discordance with the rpoB sequencing results, even after several
repetitions. However, the PRA-hsp65 database does not contain a
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profile forM. timonense, whichmay have caused this difference in
identification between the methods used.
The M. abscessus group was the predominant NTM in our
study (eight patients), followed by MAC (three patients) and M.
fortuitum (one patient).With the exception of patients C (M.mar-
seillense and M. abscessus subsp. boletii) and patient I (M. fortui-
tum and M. timonense), who presented isolates of two different
species, the remaining patients presented isolates of only one spe-
cies, allowing a better investigation of clonality. These results were
similar to those of previous studies in which the main species
belonged to the M. abscessus group (7, 23, 24). However, our re-
sults differed from those of other studies in which most of the
isolated species were MAC (3, 5). In addition, characterization of
the microbiological profile of CF patients as developed by Pas-
choal et al. (2) does not identify NTM to the species level. Cur-
rently, CF NTM colonization/infection may be related to distinct
NTM species prevalent in distinct countries, reinforcing the im-
portance of species identification in therapeutic decision making.
Brown-Elliott et al. (25) reported thatmost of the strains of the
M. abscessus group show resistance to doxycycline, ciprofloxacin,
and moxifloxacin. Only one isolate of M. abscessus subsp. boletii,
obtained from patient J, was susceptible to doxycycline (MIC, 
0.25 g/ml) and ciprofloxacin (MIC, 1 g/ml). It is expected that
the isolates belonging to M. abscessus obtained from CF patients
may show resistance to amikacin and other aminoglycosides, as
these drugs are commonly used for treatment of bacterial infec-
TABLE 1 Comparison of PRA-hsp65 and rpoB sequencing results for identification of NTM strains isolated from sputum samples of 10 CF patients




Molecular identification based on:
PRA-hsp65 rpoB sequence
A CRM 511 17/06/2009 M. abscessus type 1 M. abscessus subsp. abscessus
CRM 718 24/02/2010 M. abscessus type 1 M. abscessus subsp. abscessus
CRM 740 23/06/2010 M. abscessus type 1 M. abscessus subsp. abscessus
B CRM 641 21/10/2009 M. abscessus type 1 M. abscessus subsp. abscessus
CRM 697 11/01/2010 M. abscessus type 1 M. abscessus subsp. abscessus
CRM 720 16/04/2011 M. abscessus type 1 M. abscessus subsp. abscessus
C CRM 696 03/12/2009 M. chimerae/M. intracellulare M. marseillense
CRM 747 12/07/2010 M. abscessus type 1 M. abscessus subsp. bolletii
D CRM 512 22/06/2009 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 640 19/12/2009 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 920 20/06/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
E CRM 473 03/06/2009 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 639 02/09/2009 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
F CRM 836 19/01/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 901 21/03/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
G CRM 694 02/09/2009 M. chimerae/M. intracellulare M. marseillense
H CRM 569 06/07/2009 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 642 21/10/2009 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 719 31/03/2010 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 723 24/04/2010 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 732 02/06/2010 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 835 13/01/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 915 14/04/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 916 14/04/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 917 14/04/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 927 14/07/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 928 04/08/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 949 02/06/2010 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 950 08/11/2011 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 1009 12/03/2012 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
CRM 1010 12/03/2012 M. abscessus type 2/M. bolletii type 1 M. abscessus subsp. bolletii
I CRM 695 03/12/2009 M. fortuitum type 2 M. timonense
CRM 724a 17/06/2009 M. fortuitum type 2 M. fortuitum
CRM 725 17/06/2009 M. fortuitum type 2 M. fortuitum
CRM 726 15/07/2009 M. fortuitum type 2 M. fortuitum
J CRM 803 30/08/2010 M. abscessus type 1 M. abscessus subsp. bolletii
a CRM 724 and CRM 725 were distinct colonies isolated from the same sputum sample.
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tions, although amikacin resistance is rare among M. abscessus
isolates recovered from different sources worldwide.
Although multidrug-resistant NTM have been reported in
studies involvingCFpatients (6, 7, 26), the presentwork shows the
highest rates compared to other studies in the scientific literature.
Nevertheless, even considering infections using the ATS criteria,
only patient H presented with development of pulmonary disease
without resolution to date. The majority of the isolates from our
study (97.2%) were resistant to five or more antimicrobials, with
the exception of isolate CRM 803, obtained from patient J. Four-
teen M. abscessus subsp. bolletii isolates (13 from patient H and 1
from patient B) had amikacin MICs higher than 128 g/ml, one
M. abscessus subsp. abscessus isolate had a MIC of 64 g/ml (pa-
tient C), and two isolates had MICs of 32 g/ml (patient A). The
first isolate from patient A showed susceptibility to amikacin;
however, the two following isolates, obtained afterwards, showed
intermediate resistance. The samewas observed for patients C and
H. Themechanisms for the acquisition of NTM resistance to ami-
kacin are unknown. Nevertheless, mutations in specific regions of
the rrs and rpsL genes may confer aminoglycoside resistance in
mycobacteria (26, 27, 28).
We recovered only three MAC isolates, two M. marseillense
(CRM 694 and CRM 696) and oneM. timonense (CRM 695), and
all of them were susceptible to clarithromycin. According to the
TABLE 2 Antimicrobial susceptibilities of the NTM isolates recovered from sputum samples of CF patients in Rio de Janeiro, Brazil
Patient Isolate Organism
MICa (g/ml)
AMI CEF CIP CLA DOX MOX T/S
A CRM 511 M. abscessus subsp. abscessus 8 (S) 64 (I) 8 (R) 8 (R) 32 (R) 8 (R)  04/76 (R)
A CRM 718 M. abscessus subsp. abscessus 32 (I) 32 (I) 16 (R) 1 (S) 32 (R) 16 (R) 08/152 (R)
A CRM 740 M. abscessus subsp. abscessus 32 (I) 128 (R) 16 (R) 32 (R) 32 (R) 16 (R)  04/76 (R)
B CRM 641 M. abscessus subsp. abscessus 8 (S) 256 (R) 4 (R) 4 (I) 32 (R) 16 (R) 16/304 (R)
B CRM 697 M. abscessus subsp. abscessus 16 (S) 32 (I) 16 (R) 16 (R) 32 (R) 16 (R) 16/304 (R)
B CRM 720 M. abscessus subsp. abscessus 64 (R) 64 (I) 16 (R) 16 (R) 32 (R) 64 (R) 16/304 (R)
C CRM 747 M. abscessus subsp. bolletii 128 (R) 256 (R) 16 (R) 32 (R) 32 (R) 16 (R)  04/76 (R)
D CRM 512 M. abscessus subsp. bolletii 8 (S) 64 (I) 8 (R) 2 (S) 32 (R) 16 (R) 16/304 (R)
D CRM 640 M. abscessus subsp. bolletii 8 (S) 64 (I) 2 (I) 0.5 (S) 32 (R) 32 (R) 16/304 (R)
D CRM 920 M. abscessus subsp. bolletii 8 (S) 256 (R) 16 (R) 0.5 (S) 32 (R) 4 (R) 16/304 (R)
E CRM 473 M. abscessus subsp. bolletii 8 (S) 64 (I) 8 (R) 0.5 (S) 32 (R) 16 (R) 16/304 (R)
E CRM 639 M. abscessus subsp. bolletii 8 (S) 256 (R) 16 (R) 0.5 (S) 32 (R) 32 (R) 16/304 (R)
F CRM 836 M. abscessus subsp. bolletii 8 (S) 32 (I) 16 (R) 0.5 (S) 32 (R) 32 (R)  04/76 (R)
F CRM 901 M. abscessus subsp. bolletii 8 (S) 64 (I) 16 (R) 0.5 (S) 32 (R) 32 (R)  04/76 (R)
H CRM 569 M. abscessus subsp. bolletii 16 (S) 128 (R) 16 (R) 64 (R) 32 (R) 32 (R)  04/76 (R)
H CRM 642 M. abscessus subsp. bolletii 8 (S) 128 (R) 16 (R) 64(R) 32 (R) 32(R)  04/76 (R)
H CRM 719 M. abscessus subsp. bolletii 128 (R) 64 (I) 16 (R) 32 (R) 32 (R) 128(R) 16/304 (R)
H CRM 723 M. abscessus subsp. bolletii 128 (R) 128 (R) 16 (R) 32 (R) 32(R) 32(R) 16/304 (R)
H CRM 732 M. abscessus subsp. bolletii 128 (R) 256 (R) 16 (R) 32 (R) 32 (R) 128 (R) 16/304 (R)
H CRM 835 M. abscessus subsp. bolletii 128 (R) 64 (I) 16 (R) 64 (R) 32 (R) 32 (R) 16/304 (R)
H CRM 915 M. abscessus subsp. bolletii 128 (R) 256 (R) 16 (R) 64 (R) 32 (R) 16 (R) 16/304 (R)
H CRM 916 M. abscessus subsp. bolletii 128 (R) 64 (I) 16 (R) 64 (R) 32 (R) 32 (R) 16/304 (R)
H CRM 917 M. abscessus subsp. bolletii 128 (R) 64 (I) 16 (R) 64 (R) 32 (R) 32 (R) 16/304 (R)
H CRM 927 M. abscessus subsp. bolletii 128 (R) 64 (I) 16 (R) 64 (R) 32 (R) 16 (R) 16/304 (R)
H CRM 928 M. abscessus subsp. bolletii 128 (R) 64 (I) 16 (R) 64(R) 32 (R) 256 (R) 16/304 (R)
H CRM 949 M. abscessus subsp. bolletii 128 (R) 64 (I) 8 (R) 16 (R) 32 (R) 2 (I) 16/304 (R)
H CRM 950 M. abscessus subsp. bolletii 128 (R) 64 (I) 16 (R) 16 (R) 32 (R) 2 (I) 16/304 (R)
H CRM 1009 M. abscessus subsp. bolletii 128 (R) 64 (I) 8 (R) 16 (R) 32 (R) 2 (I) 16/304 (R)
H CRM 1010 M. abscessus subsp. bolletii 128 (R) 64 (I) 8 (R) 16 (R) 32 (R) 2 (I) 16/304 (R)
I CRM 724 M. fortuitum 8 (S) 256 (R) 8 (R) 16 (R) 32 (R) 2 (S)  04/76 (R)
I CRM 725 M. fortuitum 8 (S) 256 (R) 8 (R) 4 (I) 32 (R) 2 (S)  04/76 (R)
I CRM 726 M. fortuitum 1 (S) 256 (R) 0.5 (S) 16 (R) 32 (R) 2 (S)  04/76 (R)
J CRM 803 M. abscessus subsp. bolletii 1 (S) 64 (I) 1 (S) 32 (R) 0.25 (S) 16 (R)  04/76 (R)
a AMI, amikacin; CEF, cefoxitin; CIP, ciprofloxacin; CLA, clarithromycin; DOX, doxycycline; MOX, moxifloxacin; T/S, trimethoprim-sulfamethoxazole; R, resistant; S, susceptible;
I, intermediate.
FIG 1 Dendrogram obtained from the automated analysis of the ERIC-PCR profiles of the M. fortuitum isolates, showing the similarity coefficients (as
percentages). Dice’s coefficient was used as the algorithm for the construction of the dendrogram.
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CLSI 2011 guidelines, clarithromycin is the chosen drug for the
treatment ofMAC infections, followed bymoxifloxacin. The drug
resistance of MAC in CF patients is rare, which facilitates longer
antimicrobial treatments (25). Other drugs, such as ethambutol
and rifampin, are used in associationwith clarithromycin therapy.
In some cases, amikacin is used together with clarithromycin.
However, due to the long duration of the treatment, which may
last longer than 6 months, and the nephrotoxic and ototoxic side
effects caused by amikacin, this therapy has been abandoned (25,
28, 29). Furthermore, the present results, based on the break-
points described by Siddiqi et al. (19), indicate that the therapy
with amikacin, ethambutol, moxifloxacin, rifampin, or strepto-
mycin may be ineffective due to the high amikacin MIC for iso-
lates CRM 694 and CRM 696 (8 g/ml) and the intermediate
resistance found for other drugs.
According to the review published by Pitombo et al. (30), most
M. fortuitum strains are susceptible to amikacin, cefoxitin, cipro-
floxacin, imipenem, linezolid, and sulfamethoxazole-trim-
ethoprim; however, M. fortuitum isolates from CF patients in the
present study were resistant to cefoxitin, ciprofloxacin, doxycy-
cline, and sulfamethoxazole-trimethoprim. Isolates CRM724 and
CRM 725 also showed resistance to clarithromycin. According to
Brown-Elliott et al. (25), the M. fortuitum group presents sulfon-
amide susceptibility of 100%; however, all M. fortuitum isolates
fromCF patients in our study were resistant to sulfamethoxazole-
trimethoprim, with MICs higher than 8/152 g/ml.
ERIC-PCR is a simplemolecular tool and can be used for geno-
typing mycobacteria. A study by Sampaio et al. (31) compared
different genotyping techniques for 17 isolates of M. fortuitum
from an outbreak of infection postmammoplasty, and in this
comparison ERIC-PCR indicated clonal profiles that were identi-
cal to the gold standard technique (PFGE). ERIC-PCR is consid-
ered a fast and economic alternative to PFGE. In a study with 40
Ugandan children and teenagers with pulmonary infection caused
by M. fortuitum, ERIC-PCR revealed the presence of a clonal
group of three isolates, another group comprised of two isolates,
and also 35 distinct profiles (32).
A clonal group of M. fortuitum was recovered from patient I
and had over 95% similarity. It is interesting that even though they
had the same genotypic restriction pattern, CRM 725 and CRM
FIG 2 Dendrogram obtained from the automated analysis of the PFGE profiles of the M. abscessus subsp. abscessus isolates, showing the similarity coefficients
(as percentages). Dice’s coefficient was used as the algorithm for the construction of the dendrogram.
FIG 3 Dendrogram obtained from the automated analysis of the PFGE profiles of theM. abscessus subsp. bolletii isolates, showing the similarity coefficients (as
percentages). Dice’s coefficient was used as the algorithm for the construction of the dendrogram.
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726 showed different susceptibility profiles. Isolate CRM 724
showed the same susceptibility profile as CRM 725, as both were
isolated from the same clinical sample. In conclusion, a single
sputum sample presented two different types of colonies with
slightly different genotypic profiles; the small colony named CRM
724 and the larger one namedCRM725. The isolation ofCRM726
occurred 30 days after the isolation of the cited isolates (CRM 724
and CRM 725) and had a profile identical to CRM 725. The sus-
ceptibility profile and the genotypic profile results from isolates
obtained from this clinical case suggest multiclonal NTM coloni-
zationwith the same species, whichmay represent recent genomic
mutations in mycobacterial populations.
The PFGE results for the M. abscessus subsp. abscessus isolates
revealed two distinct genotypes: MAA 1 and MAA 2. The MAA 1
PFGE pattern comprised three isolates frompatient B and showed
two identical strains (CRM 641 and CRM 697) and one other
(CRM 720) with a similarity of 88%. The MIC data for these iso-
lates suggest that the most recent isolated strain (CRM 720) has
resistance to amikacin and has different PFGE patterns from the
others. A recent study described a patient infected withM. absces-
sus subsp. bolletii that had acquired resistance to amikacin during
therapy with the same drug (26). The genotypeMAA 2 comprised
3 clonal isolates from patient A. However, the resistance profile
was different among the three isolates. These aspects may indicate
that themolecular basis involved in the alteration of susceptibility
to drugs may not be related to the M. abscessus subsp. abscessus
genotypic profile obtained from PFGE. Further studies are re-
quired for better understanding of this.
The PFGE results for isolates identified as M. abscessus subsp.
bolletii were classified into five different genotypes (MAB 1 to 5).
Among those five genotypes, MAB 1 represented most of the M.
abscessus subsp. bolletii isolates (15). All the isolates from patient
H had this genotype, as did isolate CRM 747 from patient C and
CRM 639 obtained from patient E. CRM 639 had a profile that
differed from the other isolates by only one band. After review of
medical records, we verified that no other isolation of mycobac-
teria occurred frompatients C andEup to the datewe finished this
study, suggesting that these bacteria may have represented the
most transient microbiota of these patients. It was also very star-
tling that the MAB 1 genotype was circulating among three pa-
tients and that this same clone remains, causing severe disease in
patient H up to the present day (data not shown).
The genotype MAB 2 was comprised of isolates CRM 836 and
CRM 901 isolated from patient D, with identical molecular and
susceptibility profiles, which confirmed a patient-specific pattern.
Similarly, the genotype MAB 5 was found for two clones isolated
from the same patient (D), one isolated 18 months after the first
isolation.
PFGE for MAA andMAB 2 were evaluated by using a discrim-
inatory index, which presented values higher than 0.90. These
results confirmed the elevated discriminatory power of this
method for diversity studies of these species, as shown in previous
studies (33, 34).
The data obtained in this work will contribute to a better com-
prehension of NTM colonization/infection of CF patients. The
observed NTM characteristics are alarming, since most of the iso-
lates circulating among the patients showed resistance tomultiple
drugs. Isolation of highly resistant strains from CF patients must
be considered a significant threat to public health, mainly due to
the paucity of alternative therapy or potentially untreatable dis-
ease. Based on these findings, it is highly recommended that CF
patients be monitored for NTM infections.
These findings, which are unprecedented in a country with a
high incidence of TB, reinforce the importance of systematic and
routine research for the identification of mycobacteria to the spe-
cies level and susceptibility evaluations of antimicrobials. Studies
on monitoring of NTM transmission through respiratory equip-
ment among CF patients may also be useful, to better understand
rates of colonization and prevalence of these organisms in these
settings.
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